

Investor Update

**Positive results from FDA mid-cycle
review of Sofpironium Bromide**

April 2023

ersonal use only

Important Notice & Disclaimer

Summary information: This presentation has been prepared by Botanix Pharmaceuticals Ltd (“Botanix”) and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation (“Presentation”) (unless otherwise indicated). The following notices and disclaimers apply and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting this Presentation you represent and warrant that you are entitled to receive this Presentation in accordance with the restrictions, and agree to be bound by the limitations, contained within it. The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities law. Please refer to the section of this Presentation headed “International Offer Jurisdictions” for more information. This Presentation, and the information provided in it, does not constitute, and is not intended to constitute, financial product or investment advice, financial, legal, tax accounting or other advice, or a recommendation to acquire New Shares and does not and will not form any part of any contract for the acquisition of New Shares. It has been prepared without taking into account the objectives, financial or tax situation or particular needs of any individual.

Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek professional advice from their legal, financial, taxation or other independent adviser (having regard to the requirements of all relevant jurisdictions). Cooling off rights do not apply to the acquisition of New Shares

The information in this Presentation is general in nature and does not purport to be accurate nor complete, nor does it contain all of the information that an investor may require in evaluating a possible investment in Botanix, nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). It has been prepared by Botanix with due care but no representation or warranty, express or implied, is provided in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this Presentation by Botanix or any other party.

The information in this Presentation remains subject to change without notice. Botanix does not have any obligation to finalize, correct or update the content of this Presentation. Certain data used in this Presentation has been obtained from research, surveys or studies conducted by third parties, including industry or general publications. No reliance may be placed for any purpose whatsoever on the information contained in this Presentation or on its accuracy or completeness. Any reliance on this communication could potentially expose you to a significant risk of losing all of the funds invested by you in Botanix or the incurring by you of additional liability.

To the maximum extent permitted by law, Botanix is not responsible for updating, nor undertakes to update, this Presentation. It should be read in conjunction with Botanix’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www2.asx.com.au or at <https://botanixpharma.com/category/asx-releases/>.

Not an offer: Neither this Presentation nor any of its contents is a Prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC), nor will form the basis of any understanding, proposal, offer, invitation, contract or commitment.

Industry data: Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

Financial data: All dollar values are in United States dollars (\$) or US\$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

Forward-looking statements and forecasts: This Presentation contains certain “forward-looking statements” and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercializing product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct.

Any such forward looking statements are also based on assumptions and contingencies which are subject to change, and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic). The forward-looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix. No representation or warranty (whether express or implied) is made as to the accuracy or likelihood of fulfilment of any forward- looking statement.

Except as required by law or regulation, Botanix undertakes no obligation to finalize, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation.

No liability: The information contained in this document has been prepared in good faith by Botanix. Neither Botanix, nor any of its advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, advisers, employees and agents (**Limited Parties**) have authorised, permitted or caused the issue, lodgment, submission, dispatch or provision of this Presentation in a final form and none of them makes or purports to make any binding statement in this Presentation and there is no statement in this Presentation which is based on any statement by them.

To the maximum extent permitted by law, the Limited Parties: expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any estimates or projections and any other financial information derived therefrom, whether by way of negligence or otherwise; and

expressly exclude and disclaim all liabilities in respect of, make no representations regarding, any part of this Presentation and make no representation or warranty as to the currency, accuracy, adequacy, reliability or completeness or fairness of any statements, estimates, options, conclusions or other information contained in this Presentation.

Investors represent, warrant and agree that they have not relied on any statements made by any of the Limited Parties in relation to the issue of New Shares.

The Limited Parties make no recommendations or endorsements as to whether any recipient should participate in the offer of New Shares and, to the maximum extent permitted by law, disclaim any fiduciary relationship with any recipient.

Botanix: A leader in topical drug development



DERMATOLOGY FOCUS

New treatments for common skin diseases—such as excessive sweating (hyperhidrosis), rosacea and acne—as well as life-threatening bacterial infections



TOPICALLY DRIVEN

Targeting key indications with topical (gel) treatments that are safe, well tolerated and validated with clinical efficacy



WORLD CLASS TEAM

US based team that have been responsible for more than 30 dermatology drug developments and launches



SOFPIRONIUM BROMIDE GEL (“SB”)

First and only new drug for “primary axillary hyperhidrosis” (medical condition which results in excessive underarm sweating) already approved in Japan and sales ramping up with partner¹



MID-CYCLE REVIEW POSITIVE

FDA mid-cycle review of SB confirmed that no significant issues have been identified and approval timeline on track for September 2023

Preparing for
FDA approval of
first product in a
US\$1.6 billion
market

World class board and management team

Developed, secured approval for, and commercialised over 30 successful dermatology products



VINCE IPPOLITO
Executive Chairman

- COO of Anacor and Medicis; former President Dermavant; more than 17 years at Novartis
- More than 35 years experience in pharma with 20+ years within dermatology



HOWIE MCKIBBIN
Chief Operating Officer

- Former SVP Commercial of Dermavant, Anacor and Medicis
- 20+ years working in dermatology—launched more than 15 brands and managed over 35 dermatology products



DR PATRICIA WALKER
Chief Medical Adviser

- Former President and head R&D Brickell Biotech
- Former CMO/CSO at Kythera, Inamed and Allergan Medical responsible for multiple products including Botox and Tazorac



MATT CALLAHAN
Board Executive Director

- Serial founder and ex-investment director of two venture capital firms in life sciences
- Developed four products through FDA approval and launch



DR BILL BOSCH
Board Director

- 30+ years experience in pharma industry
- Co-inventor of SoluMatrix™ drug delivery technology and NanoCrystal® Technology



ANTHONY ROBINSON
VP of Development

- Recently Vice President R&D at Advicenne
- Senior leadership roles at Aquestive Therapeutics, Intromune and Shire Pharmaceuticals



DR JACK HOBLITZELL
SVP Pharmaceutical Development

- 30+ years leading world-class technical operations
- Senior leadership roles at Assertio Therapeutics, Pfizer, King, Ivax and Teva




DR IRA LAWRENCE
Clinical and Regulatory Adviser

- 30+ years of senior level leadership experience within the global pharmaceutical and medical device industries
- Former SVP R&D Medicis, Astellas and Fujisawa

Value inflection points accrue as FDA review progresses

Successful mid-cycle review now completed



Personal use only

Mid-cycle review meeting successfully completed with FDA

FDA's review of the NDA with each of its internal functional groups (manufacturing, pre-clinical, clinical etc.) provides preliminary notice of issues to the sponsor (Botanix)

NO SIGNIFICANT ISSUES

- ❖ No significant issues have been identified by FDA as a result of its review of product quality, non-clinical or clinical

NO SAFETY OR RISK ISSUES

- ❖ No major safety issues, no risk management or advisory board requirements

DISCUSSIONS ON FINAL ISSUES

- ❖ FDA will continue its discussions with Botanix and focus on labeling, clinical outcome assessments, patient instructions and brand name


INSPECTIONS AND RESPONSES

- ❖ Working with FDA to respond to usual information requests, review further comments and facilitate planned inspections

Hyperhidrosis

A medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature

- ❖ Hyperhidrosis affects ~16M people in the US¹
- ❖ Results from overstimulation of the nervous system (a physiological not psychological condition)¹
- ❖ 90% of axillary (underarm) patients also have it in a second region¹
- ❖ The most common age of onset for axillary hyperhidrosis patients is 12–17²
- ❖ **Market for treatments is ~US\$1.6B per annum—projected to grow to US\$2.8B by 2030³**



FREQUENTLY
CHANGE
CLOTHES



FRESHEN UP
BY WIPING OR
BATHING



PLACE NAPKINS OR
PADS UNDER THEIR
ARMS OR THEIR
POCKETS




HIDE UNDER
DARK-COLOURED,
BULKY CLOTHES

Sofpironium Bromide mechanism of action

Blocks sweat gland receptors and rapidly degrades for excretion

ersonal use only




M3 AC Receptors = Muscarinic Acetylcholine Receptors which regulate the function of sweat glands

SB Metabolite = Sofpironium Bromide is converted into a less active form to help minimize side effects

Both Phase 3 clinical study co-primary endpoints were highly statistically significant

POOLED DATA (CARDIGAN I AND II)

≥2-point improvement in HDSM-Ax-7 from baseline to end of treatment¹




SB = Sofpironium Bromide

HDSM-Ax-7 scale measures patient reported severity of axillary (underarm) hyperhidrosis

POOLED DATA (CARDIGAN I AND II)

GSP change from baseline to end of treatment¹




GSP (Gravimetric Sweat Production) is an objective measurement of underarm sweat production over 5 minutes

Secondary Efficacy Endpoint

Pooled Data (Cardigan I and II)

HDSM-Ax-7 reduction (≥ 1 -point improvement) from baseline to end of treatment¹



SB= Sofpironium Bromide

Almost **85%** of patients experienced a *statistically significant and clinically meaningful response*

Significant opportunity for a new topical agent with class leading efficacy and safety



Due to its significant psychological impact, 54% of respondents suffering from hyperhidrosis say that they would pay anything for a treatment to stop their excessive sweating¹

Independent research shows 85% of patients and dermatologists would use and prescribe Sofpironium Bromide¹

With ~13M hyperhidrosis patients in the US, a significant opportunity exists for a new topical product to address an unmet need if it is effective, convenient, and not priced prohibitively²



UNMET NEED: ~6 OUT OF 7

“I can count on one hand my total armory for treating hyperhidrosis. I need **more tools in my toolbox** and a **convenient product** for my patients.”

– DERMATOLOGIST



A rating of 4 out of 7 is high based on our experience with payers across therapeutic areas

UNMET NEED: ~4 OUT OF 7

“We are always looking for more **efficacious** therapies that are **easier to take.**”

– PAYER



UNMET NEED: ~6 OUT OF 7

“The treatments that we have are **not very convenient** and are **pretty costly**. I just feel like there are **not enough options**”

– PATIENT





TOP TWO UNMET NEEDS

- New treatment options (i.e., limited options)
- More efficacious treatments without access/cost concerns

Research indicates dermatologists would start *new* patients on Sofpironium Bromide in addition to moving *existing* patients

CURRENT PRESCRIPTION PREFERENCES


PROSPECTIVE PRESCRIPTION PREFERENCES



*Share of patients by treatment type shows a weighted average across severities

Source: 1. Triangle Insights conducted interviews with US dermatologists (n=20), US payers (n=10), US patients (n=20)

Limited dermatologist targeting plus digital strategy—expands the addressable patient population



Potential to diagnose and treat from home with telemedicine

Patients already in dermatologist's office that can be reached with a targeted sales force

Personal use only



Source: 1. International Hyperhidrosis Society, 2. Dolittle, et al, 2016, Hyperhidrosis: an update on prevalence and severity in the United States, Archives of Dermatology Research

Sofpironium Bromide has already been approved in Japan which helps de-risk FDA approval and supports commercial success



Approval Date	September 25, 2020, in Japan ¹
Indication	Primary axillary hyperhidrosis
Launch Date	November 26, 2020
Application	An applicator allows for drug application without the need for the patient to touch the product
Name	Ecclock®

Mitigation of Commercial & Clinical Risk

Clinical & Regulatory

- ❖ Japanese approval paired with strong Phase 3 clinical trial results in the US help to support safety and efficacy and de-risk SB from a regulatory standpoint

Commercial

- ❖ Inclusion on the National Health Insurance drug reimbursement price list supports the perceived need for the product from payers and suggests receptivity to Ecclock's (SBG) value proposition²
- ❖ **Initial performance in the Japanese market is promising, with year 2 sales reaching ~300K units¹**
- ❖ Japan's population is 1/3rd the size of the USA (with prevalence similar for hyperhidrosis)³ – so if this volume of sales is replicated in the USA, a substantial opportunity exists for Sofpironium Bromide

Sofpironium Bromide intellectual property summary

Sofpironium bromide is protected by strong IP in the US and other major global markets with potential significant commercial exclusivity

COMPOSITION OF MATTER

- ❖ US patent issued with claims covering compounds, compositions, and methods of use (expires 2027, excluding patent term extension targeted for 2033)
- ❖ US non-provisional and national stage applications filed covering crystalline forms and manufacturing process of SB; issued in Japan (expiry not before 2040)

METHOD OF DOSING

- ❖ US patent issued with claims covering uses of SBG for treatment of HH (expires 2034)
- ❖ National stage filings pending or allowed (Granted in EP, JP & CA)

FORMULATION

- ❖ US patents issued with claims covering novel topical compositions and uses for treatment of HH (expires 2034)
- ❖ PCT filed (national stages pending and available) covering Japan commercial formulation

APPLICATOR SYSTEM

- ❖ US provisional utility application filed for the novel applicator system (expires 2039)
- ❖ Design application filed in US (and other key jurisdictions) covering the applicator and container system (expiration not before 2034)

Executing on planned commercial and regulatory milestones

ersonal use only




NDA
SUBMISSION
COMPLETE



CALENDAR YEAR

3Q 2022



DAY 74
LETTER



4Q 2022



MID-CYCLE
REVIEW



1Q 2023



FDA
APPROVAL

3Q 2023

Offer Summary

Botanix Institutional Placement of up to A\$10 million

Offer Structure and Size	<ul style="list-style-type: none">▪ Botanix is undertaking an institutional placement to raise up to \$10 million▪ The Placement is being undertaken in a single tranche utilising the Company’s existing 10% Placement capacity under ASX Listing Rule 7.1▪ Up to approximately 111 million New Shares will be issued under the Placement (representing ~9.3% of current shares on issue)▪ Use of funds – preparation for commercial launch of SB, payment of milestones, manufacturing scale-up, regulatory costs and costs of the offer.▪ Firm commitments received from new and existing institutional investors with extensive experience investing in life sciences
Offer Price	<ul style="list-style-type: none">▪ The Placement will be conducted at an offer price of \$0.09 per New Share (“Offer Price”) represented a:<ul style="list-style-type: none">– 10% discount to the last close price on Friday, 31 March 2023 before the trading halt; and– 5.9% discount to the 30-day volume weighted average price on Friday, 31 March 2023 before the trading halt
Ranking	<ul style="list-style-type: none">▪ New Shares issued under the Placement will rank pari passu with existing Shares from their issue date
Joint Lead Managers	<ul style="list-style-type: none">▪ Jefferies (Australia) Pty Ltd and Euroz Hartleys Limited acted as Joint Lead Managers and Bookrunners to the Placement

Indicative Timetable

Placement timetable

Event	Date (Sydney, Australia time)
Trading halt	Monday, 3 April 2023
Announcement of completion of Placement, 3B, trading halt lifted	Wednesday, 5 April 2023
Settlement of the Placement	Wednesday, 12 April 2023
Allotment and normal trading of New Shares issued under the Placement	Thursday, 13 April 2023

International Offer Restrictions

International offer restrictions This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). Accordingly, this document may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance). No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities. The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.

New Zealand This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (New Zealand) (the "FMC Act"). The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who: • • • • Singapore is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act; meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act; is large within the meaning of clause 39 of Schedule 1 of the FMC Act; is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

Singapore

This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the "SFA") or another exemption under the SFA.

This document has been given to you on the basis that you are an "institutional investor" or an "accredited investor" (as such terms are defined in the SFA). If you are not such an investor, please return this document immediately. You may not forward or circulate this document to any other person in Singapore.

Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party. There are on-sale restrictions in Singapore that may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.

United Kingdom

Neither this document nor any other document relating to the offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended ("FSMA")) has been published or is intended to be published in respect of the New Shares.

The New Shares may not be offered or sold in the United Kingdom by means of this document or any other document, except in circumstances that do not require the publication of a prospectus under section 86(1) of the FSMA. This document is issued on a confidential basis in the United Kingdom to "qualified investors: within the meaning of Article 2€ of the UK Prospectus Regulation. This document may not be distributed or reproduced, nor may its contents be disclosed by recipients, to any other person in the United Kingdom.

Any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received in connection with the issue or sale of the New Shares has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of the FSMA does not apply to the Company.

In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 ("FPO"), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together "relevant persons"). The investment to which this document relates is available only to relevant persons. Any person who is not a relevant person should not act or rely on this document.

RISK FACTORS

The business, assets and operations of Botanix are subject to certain risk factors that have the potential to influence the operating and financial performance of Botanix in the future. These risks can impact on the value of an investment in the securities of Botanix. There are also general risks associated with any investment in securities. Some of these specific and general risks are outside the control of Botanix and are not capable of mitigation. The specific and general risks described in this presentation are not to be taken as exhaustive.

Before deciding to invest in Botanix, potential investors should refer to announcements made by Botanix on the ASX to ensure they understand the operations of Botanix and appreciate the risks involved with investing in Botanix. Potential investors should consult their professional advisers before making any investment decisions.

The Placement is not underwritten and there is no guarantee the amount sought will be raised.

REGULATORY RISKS

The research, development, manufacture and sale of Botanix's products is subject to a number of regulations prescribed by government authorities in Australia and overseas.

Generally, there is a high rate of failure for drug candidates proceeding through pre-clinical and clinical trials. Further, even if Botanix views the results of a trial to be positive, the FDA or other regulatory authorities may disagree with Botanix's interpretation of the data. Thus, any product deploying Botanix's technology may be shown to be unsafe, non-efficacious, difficult or impossible to manufacture on a large scale, uneconomical to market, compete with superior products marketed by third parties, fail to secure meaningful reimbursement approval, or not be as attractive as alternative treatments.

Likewise, comments from the FDA do not reflect a final decision on the information reviewed as part of any NDA submission and should not be construed to do so. These comments are preliminary and may be subject to change as FDA finalizes its review of any NDA and FDA may also identify other information that must be provided before any application can be approved. If FDA do not provide approval in a timely fashion, then the primary asset for Botanix may be reduced in value.

INNOVATIVE TECHNOLOGICAL DEVELOPMENTS

Botanix's product range includes candidates that are in pre-clinical development and need to be further tested before they can progress to human clinical trials. Pre-clinical and clinical development of Botanix's product candidates could take several years to complete, and might fail for a number of reasons including but not limited to lack of efficacy, failure to obtain regulatory approval, difficulty or failure to manufacture Botanix's products on a large scale, or toxicity. There is no guarantee that Botanix's products will be, or continue to be, commercially successful.

DEPENDENCE ON SERVICE PROVIDERS AND THIRD-PARTY COLLABORATORS

Botanix relies upon independent third-party service providers and third party collaborators including academic institutions to complete the development and commercialisation of its products. Botanix therefore is exposed to the risk that any of these parties can experience problems related to operations, financial strength or other issues, which in turn could negatively impact the progress or success of Botanix's product development efforts.

INTELLECTUAL PROPERTY

Botanix's ability to leverage its innovation and expertise depends upon its ability to protect its intellectual property including maintaining patent protection for its product candidates and their respective targets. Botanix owns or has licensed, issued and pending patent applications covering a range of potential drug candidates.

The prospect of attaining patent protection for products such as those Botanix proposes to develop is highly uncertain and involves complex and continually evolving factual and legal questions. Botanix may incur significant costs in prosecuting or defending its intellectual property rights.

Risk Factors cont.

COMPETITION RISK

The pharmaceutical sectors are highly competitive and subject to rapid and significant change. The development of pharmaceuticals is very difficult and demanding; even more so if this competition is against competitors who may have larger resources than Botanix.

A number of companies, both in Australia and overseas, may be developing products that target similar markets that Botanix is targeting. Botanix may face competition from companies with superior technologies or greater resources.

CURRENCY RISK

Revenue and expenditure in overseas jurisdictions are subject to the risk of fluctuations in foreign exchange markets. Botanix main business is carried on outside of Australia. Accordingly, revenues and payments will be made in those countries' currencies and may deviate from budgeted expectations if there are adverse currency fluctuations against the Australian dollar.

REQUIREMENT TO RAISE ADDITIONAL FUNDING

Botanix may be required to raise additional funds in the future. There is no guarantee that Botanix will be able to raise such additional capital when it is required, or on terms satisfactory to Botanix. If Botanix is unsuccessful in obtaining funding when required, this may have a material adverse effect on Botanix's business and financial condition and performance and Botanix may need to delay, scale down or cease its operations. Further, any additional capital raised may dilute shareholders' interests in Botanix.

RISK OF DELAY AND CONTINUITY OF OPERATIONS

Botanix may experience delays in achieving some or all of its milestones, including but not limited to product development, completion of trials, obtaining regulatory approvals manufacturing delays, or delays in sales or out licensing. Botanix is also dependent on amongst other things its technology, key personnel and IT systems. Botanix is also dependent on third party suppliers, which may encounter delays which can impact Botanix. Any disruption or delay to any key inputs could impact adversely on Botanix.



Operations:
3602 Horizon Drive, Suite 160
King of Prussia PA 19406

Corporate Office:
D2 661 Newcastle Street
Leederville W. Australia 600

Authorized for release by:
Vince Ippolito
Executive Chairman

22
www.botanixpharma.com

INSURANCE

Botanix insures its business and operations. However, Botanix's insurance may not be of a nature or level to provide adequate insurance cover to insure against the occurrence of all events that may impact on the operations of Botanix. The occurrence of an event that is not covered or fully covered by insurance could have a material adverse effect on the business, financial conditions and results of Botanix.

MARKET CONDITIONS

The price at which Botanix's securities are quoted on ASX may increase or decrease due to a number of factors outside Botanix's control and which are not explained by the fundamental operations and activities of Botanix, including unpredictable influences on the market for securities in general and pharmaceutical stocks in particular. These factors may cause Botanix's securities to trade at prices above or below the price at which Botanix's securities were initially acquired. Some of the factors which may affect the price of the securities include:

- fluctuations in the domestic and international market for listed stocks;
- general economic conditions in both Australia and internationally, including interest rates, inflation rates, exchange rates, commodity prices, inclusion in or removal from market indices;
- changes to government fiscal, monetary or regulatory policy, legislation or regulation; and
- the nature of competition in the markets and industries in which Botanix operates.

FORCE MAJEURE

Events may occur within or outside Australia that could affect investor sentiment or impact upon the global and Australian economies, the operations of Botanix and the price of its securities. These events include acts of terrorism, an outbreak of international hostilities, fires, floods, earthquakes, labour strikes, civil wars, natural disasters, outbreaks of disease or other man-made or natural events. These events can have an adverse effect on the demand for Botanix's products and its ability to conduct business. Botanix has only a limited ability to insure against some of these risks.

Operations:

Corporate Office:

Risk Factors cont.

RELIANCE ON KEY PERSONNEL

The responsibility of overseeing the day-to-day operations and the strategic management of Botanix depends substantially on its senior management and its key personnel. There can be no assurance given that there will be no detrimental impact on Botanix if one or more of these employees cease their employment.

COVID-19

The current COVID-19 pandemic has been having, and is likely to continue to have, a significant impact on global capital markets, commodity prices and foreign exchange rates. The COVID-19 pandemic creates particular risks and challenges for Botanix, which outsources both research and manufacturing activities, as operational progress may be slowed or arrested as jurisdictions and suppliers respond to differing conditions. While to date COVID-19 has not had a material impact on Botanix, it could have an adverse impact on Botanix's operations, financial position and prospects in the future in addition to impacting on the ability of Botanix personnel to travel and execute the planned activities and studies.

LITIGATION RISK

There is a risk that Botanix may in the future be the subject of or require to commence litigation, mediation or arbitration. The impact of such actions may have a material adverse impact on Botanix.

INSOLVENCY RISK

The Directors are unable to predict the risk of insolvency or managerial failure by any of the contractors used (or to be used in the future) by Botanix in any of its activities or the insolvency or other managerial failures by any of the other service providers used (or to be used by Botanix in the future) for any activity.

CHANGE TO LAW

Botanix may be affected by changes to laws, regulations and policy (in Australia and other countries in which Botanix operates) concerning pharmaceuticals, superannuation, taxation, trade practices and competition, government grants, incentive schemes, accounting standards and other matters. Such changes may have adverse impacts on Botanix from a financial and operational perspective.



Operations:
3602 Horizon Drive, Suite 160
King of Prussia PA 19406

Corporate Office:
D2 661 Newcastle Street
Leederville W. Australia 600

Authorized for release by:
Vince Ippolito
Executive Chairman